VAM
SEEL

Visium Asset Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Visium Asset Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1
Closed -$1.66M – 1225
2014
Q3 		$1.66M Hold
1
– – 0.02% 499
2014
Q2 		$2.48M Hold
1
– – 0.04% 359
2014
Q1 		$2.37M Buy
+1
New +$2.7M 0.04% 358

Other funds holding SEEL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return

Visium Asset Management's SEEL Position: Q4 2014 in Review

Visium Asset Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2014, closing a stake of 1 share — an estimated $1.66M sold.

Visium Asset Management first reported a position in SEEL in Q1 2014 and held it in 3 quarters. The position peaked at $2.48M in Q2 2014. 2 funds tracked by Wall St. Rank hold SEEL as of Q4 2014.

  • Visium Asset Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Visium Asset Management sold 1 Seelos Therapeutics, Inc. Common Stock share in Q4 2014, an estimated $1.66M.
  • Visium Asset Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q1 2014 and held it in 3 quarters.
  • Visium Asset Management's Seelos Therapeutics, Inc. Common Stock position peaked at $2.48M in Q2 2014.
  • 2 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.